Thomas Schall - Chemocentryx Founder, Chairman, CEO and Pres

CCXI -  USA Stock  

USD 15.32  0.21  1.39%

  Chairman
Dr. Thomas J. Schall, Ph.D., is the Chairman of the Board, President, Chief Executive Officer of ChemoCentryx, From 1993 to March 1997, Dr. Schall worked at the DNAX Research Institute, a division of ScheringPlough Corporationrationration, a pharmaceutical company. Prior to his work at the DNAX Research Institute, he worked as a scientist with Genentech, Inc., a pharmaceutical company. Dr. Schall participated in some of the earliest discoveries of chemokine system function and activities. Dr. Schall cloned one of the first chemokines to be discovered, and provided some of the earliest data for the existence of the previously unknown family of molecules which later came to be called the chemokines. Dr. Schalls laboratories have been responsible for the discovery or codiscovery of almost onethird of all known chemokine receptors
Age: 58  Chairman Since 2012  Ph.D    
650 210-2910  www.chemocentryx.com
Schall received his B.S. in biology from Northern Illinois University and his Ph.D. in cancer biology from Stanford University. We believe Dr. Schall is qualified to serve on our board of directors because of his extensive executive leadership experience, many years of service as one of our directors and our President and Chief Executive Officer and extensive scientific expertise and knowledge of the chemokine system.

Thomas Schall Latest Insider Activity

Tracking and analyzing the buying and selling activities of Thomas Schall against Chemocentryx stock is an integral part of due diligence when investing in Chemocentryx. Thomas Schall insider activity provides valuable insight into whether Chemocentryx is net buyers or sellers over its current business cycle. Note, Chemocentryx insiders must abide by specific rules, including filing SEC forms every time they buy or sell Chemocentryx'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Chemocentryx Management Efficiency

Chemocentryx has return on total asset (ROA) of (11.2) % which means that it has lost $11.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (30.1) %, meaning that it created substantial loss on money invested by shareholders. Chemocentryx management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Investment is estimated to decrease to -24.01. The current Return on Average Assets is estimated to decrease to -0.13. Chemocentryx Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 77.33 Million. The current Revenue to Assets is estimated to increase to 0.18, while Return on Average Assets are projected to decrease to (0.13) .
The company currently holds 70.03 M in liabilities with Debt to Equity (D/E) ratio of 0.19, which may suggest the company is not taking enough advantage from borrowing. Chemocentryx has a current ratio of 7.0, suggesting that it is liquid enough and is able to pay its financial obligations when due.
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Similar Executives

Found 1 records

CHAIRMAN Since

Arnold OronskyDynavax Technologies
2006
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California. Chemocentryx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people. Chemocentryx (CCXI) is traded on NASDAQ Exchange in USA. It is located in 835 Industrial Road, San Carlos, CA 94070, United States and employs 133 people. Chemocentryx is listed under Pharmaceutical Products category by Fama And French industry classification.

Chemocentryx Leadership Team

Elected by the shareholders, the Chemocentryx's board of directors comprises two types of representatives: Chemocentryx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chemocentryx. The board's role is to monitor Chemocentryx's management team and ensure that shareholders' interests are well served. Chemocentryx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chemocentryx's outside directors are responsible for providing unbiased perspectives on the board's policies.
Israel Charo, Senior Vice President - Research
Jan Hillson, Senior Vice President - Drug Development
Geoffrey Parker, Independent Director
Susan Kanaya, CFO, Sr. VP of Fin. and Secretary
Petrus Bekker, Senior Vice President - Clinical and Medical Affairs
Joseph Feczko, Independent Director
Markus Cappel, Chief Bus. Officer and Treasurer
William Fairey, COO, Executive Vice President
Thomas Edwards, Independent Director
James Tyree, Independent Director
Henry McKinnell, Director
Rajinder Singh, Senior Vice President - Research
Roger Lucas, Lead Independent Director
Rita Jain, Independent Director
Thomas Schall, Founder, Chairman, CEO and Pres

Chemocentryx Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chemocentryx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Chemocentryx without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Correlations Now

   

Global Correlations

Find global opportunities by holding instruments from different markets
All  Next Launch Module

Pair Trading with Chemocentryx

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Chemocentryx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Chemocentryx will appreciate offsetting losses from the drop in the long position's value.

Chemocentryx Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Chemocentryx and Edesa Biotech. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Trending Equities. Note that the Chemocentryx information on this page should be used as a complementary analysis to other Chemocentryx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Chemocentryx Stock analysis

When running Chemocentryx price analysis, check to measure Chemocentryx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemocentryx is operating at the current time. Most of Chemocentryx's value examination focuses on studying past and present price action to predict the probability of Chemocentryx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemocentryx's price. Additionally, you may evaluate how the addition of Chemocentryx to your portfolios can decrease your overall portfolio volatility.
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.